Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 409 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) insider Michael Alexander Smith sold 409 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $65.61, for a total transaction of $26,834.49. Following the transaction, the insider now directly owns 91,794 shares of the company’s stock, valued at $6,022,604.34. This trade represents a 0.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

• On Tuesday, May 13th, Michael Alexander Smith sold 4,407 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total transaction of $298,838.67.

Insmed Trading Up 1.3%

NASDAQ:INSM opened at $68.12 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The firm has a fifty day simple moving average of $71.57 and a 200-day simple moving average of $73.12. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $12.41 billion, a P/E ratio of -12.19 and a beta of 0.84.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.06) earnings per share. On average, equities research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after buying an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. increased its holdings in Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after buying an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Insmed by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after buying an additional 219,131 shares in the last quarter. Capital International Investors increased its holdings in Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock valued at $491,357,000 after buying an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Insmed by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock valued at $282,243,000 after buying an additional 273,759 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have commented on INSM shares. Bank of America increased their price objective on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. Guggenheim restated a “buy” rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Truist Financial upped their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Wells Fargo & Company upped their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Finally, Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.